prilocaine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
local anaesthetics 2265 721-50-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • propitocaine hydrochloride
  • prilocaine
  • propitocaine
  • (+/-)-Prilocaine
  • prilocaine hydrochloride
  • propitocaine HCl
  • prilocaine HCl
A local anesthetic that is similar pharmacologically to LIDOCAINE. Currently, it is used most often for infiltration anesthesia in dentistry.
  • Molecular weight: 220.32
  • Formula: C13H20N2O
  • CLOGP: 1.81
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 41.13
  • ALOGS: -2.83
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 33.51 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 3.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 29 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.72 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 18, 1965 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic reaction 156.26 25.81 51 809 54004 50550260
Drug intolerance 69.35 25.81 44 816 219060 50385204
Necrotising fasciitis 55.36 25.81 12 848 2592 50601672
XIIth nerve injury 45.15 25.81 5 855 8 50604256
Methaemoglobinaemia 30.21 25.81 7 853 2035 50602229

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QRS complex prolonged 90.85 39.48 18 298 4092 29570119
Cardiotoxicity 53.88 39.48 12 304 4732 29569479
Coma 50.50 39.48 18 298 39432 29534779
Respiratory failure 50.08 39.48 23 293 97108 29477103
Overdose 41.35 39.48 19 297 79800 29494411

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic reaction 150.87 27.05 51 907 68613 64429161
Drug intolerance 81.02 27.05 44 914 187948 64309826
Electrocardiogram QRS complex prolonged 70.07 27.05 18 940 9226 64488548
Necrotising fasciitis 48.42 27.05 12 946 5314 64492460
XIIth nerve injury 45.82 27.05 5 953 8 64497766
Cardiotoxicity 40.60 27.05 12 946 10262 64487512
Coma 36.13 27.05 20 938 87595 64410179
Respiratory failure 33.96 27.05 24 934 161159 64336615

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N01BB04 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, LOCAL
Amides
ATC N01BB54 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, LOCAL
Amides
FDA CS M0000897 Amides
MeSH PA D000777 Anesthetics
MeSH PA D000779 Anesthetics, Local
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35623 anticonvulsants
CHEBI has role CHEBI:36333 local anesthetics
FDA EPC N0000175682 Amide Local Anesthetic
FDA PE N0000175976 Local Anesthesia

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Premature ejaculation indication 44001008 DOID:13709
Local anesthesia indication 386761002
Bacterial septicemia contraindication 10001005 DOID:0040085
Sinus tachycardia contraindication 11092001
Myocardial infarction contraindication 22298006 DOID:5844
Shock contraindication 27942005
Parkinsonism contraindication 32798002
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Cerebral arteriosclerosis contraindication 65312002
Diabetes mellitus contraindication 73211009 DOID:9351
Decreased respiratory function contraindication 80954004
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Open wound contraindication 125643001
Seizure disorder contraindication 128613002
Bleeding contraindication 131148009
Angina pectoris contraindication 194828000
Primary dilated cardiomyopathy contraindication 195021004
Heart block contraindication 233916004
Disease of liver contraindication 235856003 DOID:409
Deficiency of cholinesterase contraindication 360607009
Angle-closure glaucoma contraindication 392291006 DOID:13550
Disorder of coronary artery contraindication 414024009
Denuded skin contraindication 418242004




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.81 acidic
pKa2 8.13 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel BLOCKER IC50 4.27 CHEMBL CHEMBL

External reference:

IDSource
4018911 VUID
N0000178903 NUI
D00553 KEGG_DRUG
1786-81-8 SECONDARY_CAS_RN
4018911 VANDF
4019902 VANDF
C0033124 UMLSCUI
CHEBI:32053 CHEBI
CHEMBL1194 ChEMBL_ID
DB00750 DRUGBANK_ID
CHEMBL1200586 ChEMBL_ID
D011318 MESH_DESCRIPTOR_UI
4906 PUBCHEM_CID
1641 INN_ID
7276 IUPHAR_LIGAND_ID
046O35D44R UNII
2557 RXNORM
5352 MMSL
5353 MMSL
d01396 MMSL
001367 NDDF
004574 NDDF
19232009 SNOMEDCT_US
387107003 SNOMEDCT_US
387299004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 0115-1468 CREAM 25 mg TOPICAL ANDA 20 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 0168-0357 CREAM 25 mg TOPICAL ANDA 25 sections
Prilocaine Hydrochloride with Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0362-9013 INJECTION, SOLUTION 40 mg SUBCUTANEOUS ANDA 24 sections
Prilocaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0362-9014 INJECTION, SOLUTION 40 mg SUBCUTANEOUS ANDA 24 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 0591-2070 CREAM 25 mg TOPICAL NDA authorized generic 24 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 0904-6989 CREAM 25 mg TOPICAL ANDA 27 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 21695-388 CREAM 25 mg TOPICAL ANDA 25 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 33261-591 CREAM 25 mg TOPICAL ANDA 21 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 42254-195 CREAM 25 mg TOPICAL ANDA 21 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 42858-029 CREAM 25 mg TOPICAL ANDA 26 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 50090-2167 CREAM 25 mg TOPICAL ANDA 20 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 50383-667 CREAM 25 mg TOPICAL ANDA 21 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 50383-667 CREAM 25 mg TOPICAL ANDA 21 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 52565-007 CREAM 25 mg TOPICAL ANDA 27 sections
LIDOCAINE AND PRILOCAINE HUMAN PRESCRIPTION DRUG LABEL 2 54868-5194 CREAM 25 mg TOPICAL ANDA 25 sections
LIDOCAINE AND PRILOCAINE HUMAN PRESCRIPTION DRUG LABEL 2 61919-443 CREAM 25 mg TOPICAL NDA 13 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 62332-582 CREAM 25 mg TOPICAL ANDA 13 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 63187-577 CREAM 25 mg TOPICAL NDA authorized generic 24 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 63739-054 CREAM 25 mg TOPICAL ANDA 17 sections
Oraqix HUMAN PRESCRIPTION DRUG LABEL 2 66312-110 GEL 25 mg PERIODONTAL NDA 27 sections
Citanest Forte HUMAN PRESCRIPTION DRUG LABEL 2 66312-540 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA 24 sections
Citanest Forte DENTAL HUMAN PRESCRIPTION DRUG LABEL 2 66312-580 INJECTION, SOLUTION 40 mg PARENTERAL ANDA 24 sections
Citanest Plain HUMAN PRESCRIPTION DRUG LABEL 1 66312-630 INJECTION, SOLUTION 40 mg SUBMUCOSAL ANDA 24 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 68071-1625 CREAM 25 mg TOPICAL ANDA 22 sections
Relador Pak with Occlusive Dressing HUMAN PRESCRIPTION DRUG LABEL 2 69166-105 CREAM 25 mg TOPICAL ANDA 26 sections
LIDOPRIL HUMAN PRESCRIPTION DRUG LABEL 2 69336-825 CREAM 25 mg TOPICAL NDA 11 sections
LIDOPRIL XR HUMAN PRESCRIPTION DRUG LABEL 2 69336-826 CREAM 25 mg TOPICAL NDA 11 sections
PRILOLID HUMAN PRESCRIPTION DRUG LABEL 2 69336-828 CREAM 25 mg TOPICAL NDA 11 sections
Lidocaine and Prilocaine Cream HUMAN PRESCRIPTION DRUG LABEL 2 70512-030 CREAM 25 mg TOPICAL ANDA 13 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 71589-017 CREAM 25 mg TOPICAL ANDA 16 sections